ECC5004 further strengthens our existing pipeline addressing both incretin and non-incretin pathways, including our GLP-1/glucagon dual agonist [AZD9550] and long-acting amylin analogue [AZD6234]. Preliminary results from a Phase I trial in the United States suggest ECC5004 has a different profile from most of the current drugs, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo
The simple log you keep may change the chaos of side effects into a clear, fixable pattern
Lipman warns of the harm in fad diets and advocates for eating close to nature and staying away from processed foods
When taken together, these gastrointestinal effects may be more pronounced
Which anti-hair loss products contain biomimetic peptides or copper peptides
In this episode of The Diary Of A CEO, psychiatrist Anna Lembke and Steven Bartlett explore how dopamine affects pleasure, addiction, and human behavior
